Dr. Wang on Unique Properties of KTE-X19 in Relapsed/Refractory MCL

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses unique properties of the investigational CAR T-cell therapy KTE-X19 in relapsed/refractory mantle cell lymphoma (MCL).

In February 2020, the FDA granted a priority review designation to a biologics license application for KTE-X19 for the treatment of adult patients with relapsed/refractory MCL.

In the phase 2 ZUMA-2 trial, a single infusion of KTE-X19 elicited a 93% objective response rate and a 67% complete response rate.

KTE-X19 utilizes the costimulatory molecule CD28, whereas other novel CAR T-cell therapies use the costimulatory signal 4-1BB.

Pending approval, KTE-X19 could be used following BTK inhibition in patients who do not respond to BTK inhibitors or in patients with high-risk disease who respond for a short duration of time, concludes Wang.